key: cord-0926186-xq8fbj9e authors: Janssens, Geert O.; Mandeville, Henry C.; Timmermann, Beate; Maduro, John H.; Alapetite, Claire; Padovani, Laetitia; Horan, Gail; Lassen-Ramshad, Yasmin; Dieckmann, Karin; Ruebe, Christian; Thorp, Nicky; Gandola, Lorenza; Ajithkumar, Thankamma; Boterberg, Tom title: A rapid review of evidence and recommendations from the SIOPE Radiation Oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises date: 2020-04-27 journal: Radiother Oncol DOI: 10.1016/j.radonc.2020.04.035 sha: 207e8385634d4b5aa62cacb7abf4fa077a810c46 doc_id: 926186 cord_uid: xq8fbj9e Abstract Objective To derive evidence-based recommendations for the optimal utilisation of resources during unexpected shortage of radiotherapy capacity. Methods and materials We have undertaken a rapid review of published literature on the role of radiotherapy in the multimodality treatment of paediatric cancers governing the European practice of paediatric radiotherapy. The derived data has been discussed with expert paediatric radiation oncologists to derive a hierarchy of recommendations. Results The general recommendations to mitigate the potential detriment of an unexpected shortage of radiotherapy facilities include: (1) maintain current standards of care as long as possible (2) refer to another specialist paediatric radiotherapy department with similar level of expertise (3) prioritise use of existing radiotherapy resources to treat patients with tumours where radiotherapy has the most effect on clinical outcome (4) use chemotherapy to defer the start of radiotherapy where timing of radiotherapy is not expected to be detrimental (5) active surveillance for low-grade tumours if appropriate and (6) consider iso-effective hypofractionated radiotherapy regimens only for selected patients with predicted poor prognosis. The effectiveness of radiotherapy and recommendations for prioritisation of its use for common and challenging paediatric tumours are discussed. Conclusion This review provides evidence-based treatment recommendations during unexpected shortage of paediatric radiotherapy facilities. It has wider applications for the optimal utilization of facilities, to improve clinical outcome in low- and middle-income countries, where limited resources continue to be a challenge. To derive evidence-based recommendations for the optimal utilisation of resources during unexpected shortage of radiotherapy capacity. We have undertaken a rapid review of published literature on the role of radiotherapy in the multimodality treatment of paediatric cancers governing the European practice of paediatric radiotherapy. The derived data has been discussed with expert paediatric radiation oncologists to derive a hierarchy of recommendations. The general recommendations to mitigate the potential detriment of an unexpected shortage of radiotherapy facilities include: (1) maintain current standards of care as long as possible (2) refer to another specialist paediatric radiotherapy department with similar level of expertise (3) prioritise use of existing radiotherapy resources to treat patients with tumours where radiotherapy has the most effect on clinical outcome (4) use chemotherapy to defer the start of radiotherapy where timing of radiotherapy is not expected to be detrimental (5) active surveillance for low-grade tumours if appropriate and (6) consider iso-effective hypofractionated radiotherapy regimens only for selected patients with predicted poor prognosis. The effectiveness of radiotherapy and recommendations for prioritisation of its use for common and challenging paediatric tumours are discussed. This review provides evidence-based treatment recommendations during unexpected shortage of paediatric radiotherapy facilities. It has wider applications for the optimal utilization of facilities, to improve clinical outcome in low-and middle-income countries, where limited resources continue to be a challenge. With the current Covid 19 pandemic,, healthcare systems are severely strained [1] [2] [3] . So far, infection and severe complications have been less common in children 4 . Nevertheless the pandemic is expected to have an impact on the capacity to deliver paediatric radiotherapy, particularly where general anaesthesia is required, due to shortages of personnel, protective equipment, ventilators and machine time, as well as coping infected children and families 5, 6 . Sudden shortage of resources may also occur during other natural disasters and following machine failures, including particle beam facilities 7 . Limited radiotherapy resources are a major obstacle in improving outcomes in low-and middle-income countries where more than two-thirds of paediatric cancers are diagnosed 8 . National guidelines are being issued to provide continuous adult cancer care without increasing the risk of COVID infection 9, 10 . Provision of uninterrupted and effective paediatric cancer care faces numerous challenges: most childhood cancers are aggressive, necessitating urgent treatment, most children are treated in international collaborative trials 4 and increasingly paediatric tumours are prioritized for treatment with proton therapy, which may entail travelling some distance. In an attempt to minimize the potential detriment on clinical outcomes for children with cancer from interruption of radiotherapy services, European paediatric radiation oncology experts have undertaken a rapid review of the role of radiotherapy in the multidisciplinary care of childhood cancers, and considered alternatives for radiotherapy when it is impossible to deliver the internationally acceptable standard of care. This guideline attempts to standardize approaches to paediatric radiotherapy in times of intense resource constraints to deliver safe, high quality treatment. General measures to mitigate detrimental clinical effects in an unexpected shortage of radiotherapy facilities  Current standard treatments, whether in trials or using approved guidelines, should be maintained if possible. Consider suspension of trials if the additional resources needed to run them become unavailable.  Consider referral to another specialist paediatric radiotherapy department.  Prioritise using existing radiotherapy resources to treat patients with tumours where radiotherapy has a high impact on outcome.  Standard or maintenance chemotherapy can be used to defer radiotherapy in chemosensitive tumours where this delay is not expected to be detrimental (e.g. rhabdomyosarcoma and Ewing sarcoma, medulloblastoma, ependymoma, and germ cell tumours presenting with metastases.)  Consider active surveillance (for WHO grade I-II primary central nervous system lowgrade gliomas and craniopharyngiomas after initial biopsy or debulking surgery).  Consider isoeffective hypofractionated radiotherapy schedules (which also reduce overall treatment time), changing dose per fraction from 1.6-1.8 Gy to above 2.0 Gy, for selected poor prognosis patients where radiotherapy cannot be safely deferred, ( neuroblastoma, rhabdomyosarcoma, Ewing sarcoma and high-grade or diffuse midline gliomas.) .  For highly proliferative tumours (rhabdomyosarcoma, Ewing sarcoma, medulloblastoma, germ cell tumours, and atypical teratoid rhabdoid tumours [ATRT}), treatment gap corrections should be applied if the planned duration of treatment is extended by > 1 week.  Omit radiotherapy in patients with poor prognostic tumours and or who need palliative care if symptom can be controlled by other measures 12, 13 .  Any deviation from standard of care radiotherapy should be agreed in multi-disciplinary team (MDT) meetings. The following section provides a summary of evidence for the effectiveness of radiotherapy and recommendations for treatment of common and challenging paediatric tumours: (Level II) o For infant medulloblastoma, chemotherapy is generally adopted to delay or avoid the need for radiotherapy 41, 42 (Level I) o Hypofractionated radiotherapy has not been studied in standard adjuvant treatment for medulloblastoma. Hypofractionated regimens provide effective palliation in a select group of patients considered for reirradiation 43 o Although chemo-sensitive, germinoma is not chemo-curable and radiotherapy has a major role in local control and cannot be omitted 63,64 (level 2) o In localized germinoma, ventricular irradiation to reduce regional subependymal relapse necessitates 24 Gy at 1.6 Gy per fraction 65 This rapid review and recommendation will serve only as a guide to MDTs and are not meant to replace the important network of national and international paediatric radiotherapy experts that regularly give advice. We wish to highlight the importance of recording outcomes for children who receive radical radiotherapy where there have been modifications in fractionation or timing of treatment due to unexpected shortage of facilities such as during the COVID-19 epidemic so that there can be shared learning in the future. There are no conflicts of interest to declare. We thank Prof Ann Barrett for critical reading of the manuscript. well-conducted cohort studies. Editor-in-Chief Dear Prof. Baumann, On behalf of the authors I submit the above manuscript for favour of publication in your esteemed journal. We confirm that this work has not been published previously or submitted elsewhere. The authors declare no conflict of interest. Yours sincerely TV Ajithkumar  Currently there are no recommendations for the optimal utilisation for paediatric radiotherapy facilities during unexpected shortage. Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries COVID-19: protecting health-care workers Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak Challenges posed by COVID-19 to children with cancer The Lancet O. COVID-19: global consequences for oncology Clinical Characteristics of Coronavirus Disease 2019 in China Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients Global child health priorities: what role for paediatric oncologists? The official French guidelines to protect patients with cancer against SARS-CoV-2 infection A new system for grading recommendations in evidence based guidelines Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers (Basel) 2020den Heuvel-Eibrink MM Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, noninferiority, randomised controlled trial Treatment of pulmonary metastases in children with stage IV nephroblastoma with risk-based use of pulmonary radiotherapy Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma Hypofractionated Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Tumours in Children and Young Adults Outcomes in intermediate-risk pediatric lymphocytepredominant Hodgkin lymphoma: A report from the Children's Oncology Group Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET >/= 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial International Lymphoma Radiation Oncology G. Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Etude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients Single-Dose Daily Fractionation Is Not Inferior to Twicea-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study The Total Body Irradiation Schedule Affects Acute Leukemia Relapse After Matched T Cell-Depleted Hematopoietic Stem Cell Transplantation Childhood Acute Lymphoblastic Leukemia Collaborative G. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031) Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961 Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial Results of three-dimensional stereotactically-guided radiotherapy in recurrent medulloblastoma Reirradiation for recurrent medulloblastoma Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91 Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Societe Francaise de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013 Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis Thalamic high-grade gliomas in children: a distinct clinical subset? Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study Optimal Timing of Radiotherapy Following Gross Total or Subtotal Resection of Glioblastoma: A Real-World Assessment using the National Cancer Database Outcomes of multidisciplinary management in pediatric low-grade gliomas Phase II trial of conformal radiation therapy for pediatric low-grade glioma A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (